IMBRUVICA® CLL/SLL Cost
Coverage and Cost
When you have support, such as help understanding your insurance coverage and potential ways to pay for IMBRUVICA®, you may feel more confident during treatment. The IMBRUVICA® By Your Side patient support program is here to help answer some of your questions about the financial aspects of taking IMBRUVICA®.
Learn more about your insurance coverage and potential financial support options.
Call the IMBRUVICA® By Your Side patient support program
1-888-YourSide (1-888-968-7743)
Monday-Friday, 8:00am-8:00pm ET
IMBRUVICA® Copay Card
If you have commercial insurance, you could get IMBRUVICA® for as little as
$0
per prescription*
*Eligible patients may pay as little as $0 per prescription of IMBRUVICA®. Rules and maximum limits apply. Patients currently using the IMBRUVICA® Copay Card are not eligible for retroactive billing or reimbursement of previous copays. The IMBRUVICA® Copay Card is available to patients with commercial prescription coverage for IMBRUVICA® who meet eligibility criteria. The IMBRUVICA® Copay Card cannot be used by patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs, including Medicare Part D, Medicare Advantage Plan, Medicaid, Medigap, VA, DOD, and TRICARE, or where prohibited by law or the patient’s health insurance provider. The IMBRUVICA® Copay program may be updated or discontinued at any time without notice.
Wholesale Acquisition Cost (WAC)
The Wholesale Acquisition Cost (WAC), also known as the list price, of a 30-day supply of IMBRUVICA® is $14,920.28† as of January 2021. A majority of patients do not pay full list price once insurance coverage is applied.
†The list price for a 30-day supply of IMBRUVICA® (ibrutinib) 420-mg tablets, which is the recommended dose for CLL.
Understanding Insurance for CLL Patients‡
| If you have: | You could pay: |
| Commercial Insurance (usually provided by an employer) | As little as $0 per month* with the IMBRUVICA® Copay Card. Learn More and Enroll Here |
| Medicare (Part D and LIS) |
Most patients with Medicare pay between $0 and $48 per month for IMBRUVICA® in CLL.‖ This number represents Medicare Part D, including those with LIS. Actual out-of-pocket costs may vary based on dosing, indication, site of care, insurance coverage, and your eligibility for support programs (some of which require you to apply for the support, like independent charitable foundations). The information below is based on the benefit structure for Medicare Part D and LIS. Please see Medicare.gov for more information. Medicare Part D Most Medicare patients have standard Part D prescription coverage, which has different costs depending on deductibles and coverage gaps. With standard Part D prescription coverage, you could pay $746–$2,997 per month, depending on coverage phase. Monthly out-of-pocket costs for IMBRUVICA® may vary depending on coverage phase and other medications you may be taking. Medicare Low Income Subsidy Eligible patients may be able to access brand name drugs for less than $10 per month. You may be eligible for the Extra Help program provided by the Social Security Administration. We can help you understand what these costs mean to you by calling 1-888-968-7743. |
| Medicaid | $20.00 or less per month, depending on state plan. |
| Other Insurance (VA, DOD, TRICARE, others) | Because coverage varies by plan, call 1-888-968-7743 to find out how much IMBRUVICA® will cost for you. |
| Uninsured or if you cannot afford your medication | Pharmacyclics and Janssen are committed to helping the uninsured gain access to our medicine. Call 1-888-968-7743 or visit www.pparx.org for assistance. |
‡Important Details About Understanding Your Individual Costs:
Your type of health or prescription insurance plan will determine exactly how much you will pay. The benefit structure is based on the publicly available information for Medicare Part D, LIS, and Medicaid and cost is accurate as of January 2021 for a 30-day supply of IMBRUVICA® (420-mg dose).
*Eligible patients may pay as little as $0 per prescription of IMBRUVICA®. Rules and maximum limits apply. Patients currently using the IMBRUVICA® Copay Card are not eligible for retroactive billing or reimbursement of previous copays. The IMBRUVICA® Copay Card is available to patients with commercial prescription coverage for IMBRUVICA® who meet eligibility criteria. The IMBRUVICA® Copay Card cannot be used by patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs, including Medicare Part D, Medicare Advantage Plan, Medicaid, Medigap, VA, DOD, and TRICARE, or where prohibited by law or the patient’s health insurance provider. The IMBRUVICA® Copay program may be updated or discontinued at any time without notice.
‖Approximately 75% of US patients in this category pay an amount in this range. Actual out-of-pocket costs may vary based on dosing, indication, site of care, insurance coverage, and your eligibility for support programs (some of which require you to apply for the support, like independent charitable foundations). Contact your insurance provider for more details on your individual plan. Out-of-pocket cost estimates are based on approved pharmacy claims, normalized to a 30-days’ supply, after application of insurance benefits. Costs do not include medical claims and starter kits. Note: This is based on information licensed from IQVIA™: IQVIA™ Out of Pocket Cost (OPC Tool) for the period January 2020 – December 2020, reflecting estimates of real-world activity. All rights reserved.
Other Resources
Johnson & Johnson Patient Assistance Foundation, Inc.
The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, nonprofit organization that is committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies. To see if you might qualify for assistance, please contact a JJPAF program specialist at 800-652-6227 (Monday – Friday, 9:00 AM to 6:00 PM ET) or visit the foundation website at JJPAF.org.
